The changing face of the HIV epidemic in western Europe: What are the implications for public health policies?

Lancet

Volumn 364, Issue 9428, 2004, Pages 83-94

  Hamers, Françoise F ^a   Downs, Angela M ^a  

^a INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; BISEXUALITY; DRUG USE; EPIDEMIC; HEALTH CARE POLICY; HEALTH ECONOMICS; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MIGRATION; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROSTITUTION; PUBLIC HEALTH; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SIDE EFFECT; VIRUS TRANSMISSION; VULNERABLE POPULATION; WESTERN EUROPE; DISEASE TRANSMISSION; EUROPE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DISEASE OUTBREAKS; EUROPE; HEALTH POLICY; HIV INFECTIONS; HUMANS; PREVALENCE; PROSTITUTION; RISK FACTORS; SEXUAL BEHAVIOR; TRANSIENTS AND MIGRANTS;

EID: 3042740594     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16594-X     Document Type: Review

References (120)

1. du Bois RM, Branthwaite MA, Mikhail JR, Batten JC. Pneumocystis carinii and cytomegalovirus infections. Lancet. 2:1981;1339
2. Rozenbaum W, Coulaud JP, Saimot AG, Klatzmann D, Mayaud C, Carette MF. Multiple opportunistic infection in a male homosexual in France. Lancet. 1:1982;572-573
3. Vilaseca J, Arnau JM, Bacardi R, Mieras C, Serrano A, Navarro C. Kaposi's sarcoma and toxoplasma gondii brain abscess in a Spanish homosexual. Lancet. 1:1982;572
4. WHO. Acquired immunodeficiency syndrome (AIDS). Situation in Europe as of 31 December 1985. Wkly Epidemiol Rec 1986; 61: 125-28.
5. Downs AM, Heisterkamp SH, Rava L, Houweling J, Jager JC, Hamers FF. Back-calculation by birth cohort, incorporating age-specific disease progression, pre-AIDS mortality and change in European AIDS case definition. European Union Concerted Action on Multinational AIDS Scenarios. AIDS. 14:2000;2179-2189
6. Dubois-Arber F, Paccaud F. Assessing AIDS/HIV prevention: what do we know in Europe? Soz Praventivmed. 39:(suppl 1):1994;S3-13
7. Pollak M, Dür W, Vincineau M, et al. Evaluating AIDS prevention for men having sex with men: the West European experience. Soz Praventivmed. 39:(suppl 1):1994;S47-60
8. Rezza G, Rota MC, Buning E, Hausser D, O'Hare P, Power R. Assessing HIV prevention among injecting drug users in European Community countries. Soz Praventivmed. 39:(suppl 1):1994;S61-78
9. Hamers F. AIDS associated with blood transfusion and haemophilia in Europe. BMJ. 312:1996;847-848
10. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion. 42:2000;966-972
11. Alvarez M, Oyonarte S, Rodriguez PM, Hernandez JM. Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion. 42:2000;994-998
12. Velati C, Romana L, Baruffi L, Pappalettera M, Carreri V, Zanetti AR. Residual risk of tranfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion. 42:2000;983-993
13. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang. 84:2003;274-286
14. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS surveillance in Europe, mid-year report, 2003. Saint-Maurice: Institut de Veille Sanitaire, 2003, number 69. http://www.eurohiv.org/reports/report_69/pdf/ rapport_eurohiv_69.pdf (accessed 10 April 2004).
15. Rey D, Obadia Y, Carrieri MP, Moatti JP. HIV screening for pregnant women in south eastern France: evolution -1994-1996. Eur J Obstet Gynecol Reprod Biol ; 76. 1998:1992;5-9
16. D'Ubaldo C, Vucetich A, Pardi G, Ippolito G, Puro V. Testing for HIV infection in pregnant women at the obstetric centers in Italy. Minerva Ginecol 1999; 51: 7-14. In Italian.
17. Lindgren S, Bohlin AB, Forsgren M, et al. Screening for HIV-1 antibodies in pregnancy: results from the Swedish national programme. BMJ. 307:1993;1447-1451
18. Kvam BM, Aavitsland P, Nilsen O, Lystad A. Attitude of pregnant women to routine voluntary antenatal HIV testing. Tidsskr Nor Laegeforen 2000; 120: 2895-2900. In Norwegian.
19. Health Service Circular. Reducing mother to baby transmission of HIV (HSC 1999/183). London: NHS Executive, 1999.
20. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 15:2001;761-770
21. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 16:2002;1663-1671
22. Lot F, Pillonel J, Pinget R, Cazein F, Gouezel P, Laporte A. Diminution brutale du nombre de cas de sida; rôle des nouvelles stratégies? Bulletin Epidemiologique Hebdomadaire 1997; 11: 43-45. http://www.invs.sante.fr/ beh/1997/9711/index.html (accessed Jan 6, 2004). In French.
23. Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study. AIDS. 12:1998;1195-1201
24. Aalen OO, Farewell VT, De Angelis D, Day NE, Gill ON. New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. AIDS. 13:1999;103-108
25. Hamers FF, Downs AM, Infuso A, Brunet JB. Diversity of the HIV/AIDS epidemic in Europe. AIDS. 12:(suppl A):1998;S63-70
26. UNAIDS/WHO. AIDS epidemic update: December 2003. Geneva: UNAIDS, 2003. http://www.unaids.org/Unaids/EN/Resources/Publications/Corporate+publications/ AIDS+epidemic+update+-+December+2003.asp (accessed Jan 14, 2004).
27. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 7:2002;257-266
28. Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med. 2:2001;52-58
29. Health Protection Agency, SCIEH, ISD, National Public Health Service for Wales, CDSC Northern Ireland and the UASSG. Renewing the focus. HIV and other sexually transmitted infections in the United Kingdom in 2002. London: Health Protection Agency, 2003. http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/ publications/annual2003/annual2003.pdf (accessed Jan 26, 2004).
30. Hamers FF, Infuso A, Alix J, Downs AM. Current situation and regional perspective of HIV/AIDS surveillance in Europe. J Acquir Immune Defic Syndr. 32:(suppl 1):2003;S39-48
31. European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2003. The state of the drugs problem in the European Union and Norway. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2003. http://annualreport.emcdda.eu.int/en/home-en.html (accessed Jan 19, 2004).
32. UNAIDS. Report on the global HIV/AIDS epidemic. July 2002. Geneva: UNAIDS, 2002. http://www.unaids.org/Unaids/EN/Resources/Publications/ Corporate+publications/Report+on+the+global+HIV_AIDS+epidemic+2002+.asp (accessed Jan 14, 2004).
33. Robert Koch Institut. Zur entwicklung der HIV-epidemie in Deutschland. Epidemiologisches Bulletin 2003; 48/2003: 395-397. http://www.rki.de/INFEKT/ EPIBULL/2003/48_03.PDF (accessed Jan 30, 2004).
34. United Nations Population Division. World population prospects: the 2000 revision. New York: United Nations, 2001.
35. Gras L, van Sighem A, van Valkengoed I, Zaheri S, de Wolf F, on behalf of the Netherlands collaborative HIV treatment centres. Monitoring of human immunodeficiency virus (HIV) infection in the Netherlands, 2003. Amsterdam: HIV Monitoring Foundation, 2003.
36. Op de Coul EL, van Valkengoed IG, van Sighem AI, de Wolf F, van de Laar MJ. HIV and AIDS in the Netherlands. 1 December 2003. RIVM rapport 441100018. Bilthoven; RIVM, 2003. http://www.rivm.nl/bibliotheek/rapporten/441100018.pdf (accessed Jan 27, 2004).
37. Semaille C. Compulsory notification of HIV infection within a new system for anonymous reporting of notifiable diseases in France. Eurosurveillance Weekly 2003; 7: 030320. http://www.eurosurveillance.org/ew/2003/030320.asp#4 (accessed Jan 26, 2004).
38. Suligoi B, Pezzotti P, Boros S, Urciuoli R, Rezza G, and the HIV Study Group. Epidemiological changes in AIDS and HIV infection in Italy. Scand J Infect Dis Suppl 2003; 35 (suppl 106): 12-16.
39. Sasse A, Liesnard C, van der Groen G, et al. Recent increase in diagnoses of HIV infections based on surveillance system data in Belgium. AIDS. 14:2000;2798-2800
40. National Disease Surveillance Centre (NDSC). National Disease Surveillance Centre Annual Report 2002. Dublin: National Disease Surveillance Centre, 2003. http://www.ndsc.ie/d813.PDF (accessed Jan 12, 2004).
41. Hamouda O, Marcus U. Current trends in the HIV/AIDS epidemic in Germany. Eurosurveillance Weekly 2003; 7: 030424. http://www.eurosurveillance.org/ew/ 2003/030424.asp (accessed Jan 24, 2004).
42. Gebhardt M. Marked increase of positive test results in Switzerland. Eurosurveillance Weekly 2003; 7: 030508. http://www.eurosurveillance.org/ew/ 2003/030508.asp (accessed Jan 27, 2004).
43. Office Fédéral de la Santé Publique. Sida et VIH en Suisse. Situation épidémiologique à fin 2002. Berne: Office Fédéral de la Santé Publique, 2003. http://www.bag.admin. ch/infekt/publ/wissenschaft/f/jahresb.pdf (accessed Jan 23, 2004). In French.
44. Ministerio de Sanidad Y Consumo. http://www.msc.es/Diseno/ enfermedadesLesiones/enfermedades_transmisibles.htm (accessed Jan 29, 2004). In Spanish.
45. Moreno C, Irisarri F, Urtiaga M, et al. Epidemiological surveillance of HIV/AIDA infections in Navarra between 1985 and 2002. An sis sanit Navar 2003; 26: 269-275. In Spanish.
46. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS Surveillance in Europe, End-year report, 2002. Saint-Maurice: Institut de Veille Sanitaire, 2003, number 68. http://www.eurohiv.org/reports/report_68/pdf/ report_eurohiv_68.pdf (accessed Jan 13, 2004).
47. Staten Serum Institut. HIV/AIDS Annual Report 2002. EPI-NEWS No.34 2003. National surveillance of communicable diseases. Copenhagen: Staten Serum Institut, 2003. http://www.ssi.dk/graphics/en/news/epinews/2003/pdf/ 2003_34_hivaids.pdf (accessed Jan 13, 2004).
48. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS. 16:2002;1945-1951
49. EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS. 17:(suppl 2):2003;S3-26
50. Ministerio de Sanidad y Consumo. Encuesta hospitalaria de pacientes VIH/SIDA resultados 2002 y analysis de la evolucion 1995-2002. Madrid: Secretaria del Plan Nacional sobre el Sida, 2003. http://www.msc.es/profesional/ preProSalud/sida/pdfs/Hospitales_2002.pdf (accessed Jan 28, 2003).
51. Mocroft A, Madge S, Johnson AM, et al. Comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 22:1999;369-378
52. Rapiti E, Porta D, Forastiere F, Fusco D, Perucci CA. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group. Epidemiology. 11:2000;496-501
53. van Asten LC, Boufassa F, Schiffer V, et al. Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health. 13:2003;347-349
54. Blaxhult A, Mocroft A, Phillips A, et al. Does European or non-European origin influence health care and prognosis for HIV patients in Europe? The EuroSIDA Study Group. HIV Med. 1:1999;2-9
55. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS Surveillance in Europe, mid-year report 2002, number 67. Saint-Maurice: Institut de Veille Sanitaire, 2002. http://www.eurohiv.org/reports/report_67/pdf/ report_eurohiv_67.pdf (accessed Jan 23, 2004).
56. Adam P, Hauet E, Caron C. Increasing risk taking and IST among gays. Preliminary results of the gay press survey 2000. Saint-Maurice: Institut de Veille Sanitaire, 2001. http://www.invs.sante.fr/publications/ rap_press_gay_1101/rapport_presse_gay.pdf (accessed Jan 23, 2004).
57. Observatoire français des drogues et des toxicomanies. Report to the EMCDDA by the Reitox National Focal Point. France drug situation 2002. Paris: OFDT, 2003. http://www.ofdt.fr/BDD/publications/docs/nr03fr.pdf (accessed 30 January 2004). In French.
58. Emmanuelli J, Jauffret-Roustide M, Barin F. Epidémiologie du VHC chez les usagers de drogues, France, 1993-2002. Bulletin Epidemiologique Hebdomadaire 2003: 16-17/2003: 97-99. http://www.invs.sante.fr/beh/2003/16_17/ beh_16_17_2003.pdf (accessed Jan 28, 2003). In French.
59. Op de Coul EL, Fennema JS, van den Hoek JA, et al. HIV-infecties en aids in Nederland: prevalentie en incidentie, 1987-2002. Capita selecta on HIV/AIDS p 1-9. Alphen aan de Rijn: Van Zuiden Communications BV, 2003. In Dutch.
60. Centre d'Estudis Epidemiologics sobre l'HIV/Sida de Catalunya (CEESCAT). SIVES 2001 Integrated HIV/AIDS surveillance system of Catalonia. Barcelona: Departament de Sanitat I Seguretat Social, 2001. http://www.gencat.net/sanitat/ depsan/units/sanitat/pdf/sivesing.pdf (accessed Jan 30, 2004).
61. Health Protection Agency, Institute of Child Health, London, SCIEH. Supplementary data tables of the Unlinked Anonymous Prevalence Monitoring Programme: data to the end of 2002. London: Health Protection Agency, December 2003. http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/hiv/epidemiology/ ua.htm (accessed Jan 30, 2004).
62. Health Protection Agency, SCIEH, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, UASSG. Shooting Up: Infections among injecting drug users in the United Kingdom 2002. London: Health Protection Agency, 2003. http://www.show.scot.nhs.uk/scieh/documents/IDUAnnReport/ ShootingUp.pdf (accessed Jan, 2004).
63. Nicoll A, Hamers FF. Are trends of HIV, gonorrhoea and syphilis worsening in western Europe? BMJ. 324:2002;1324-1327
64. Martin IM, Ison CA, London Gonococcal Working Group. Rise in gonorrhoea in London, UK. Lancet 2000; 355: 623.
65. Fenton KA, Rogers PA, Simms I, Maguire H, Catchpole M. Increasing gonorrhoea reports - not only in London. Lancet. 355:2000;1907
66. Stolte IG, Dukers NH, de Wit JB, Fennema JS, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect. 77:2001;184-186
67. Johansen JD, Smith E. Gonorrhoea in Denmark: high incidence among HIV-infected men who have sex with men. Acta Derm Venereol. 82:2002;365-368
68. Couturier E, Michel A, Basse-Guérineau AL, Semaille C. Surveillance of syphilis in mainland France, 2000-2002. Bull Epidemiol Hebdomadaire 2004; 3/2004: 9-12. http://www.invs.sante.fr/beh/2004/03/ beh_03_2004.pdf (accessed Jan 17, 2004). In French.
69. Cusini M, Ghislanzoni M, Bernardi C, et al. Syphilis outbreak in Milan, Italy. Sex Transm Infect. 80:2004;154
70. Herida M, Sednaoui P, Goulet V. Gonorrhoea surveillance system in France: 1986-2000. Sex Transm Dis. 31:2004;209-214
71. Hart GJ, Flowers P, Der GJ, Frankis JS. Homosexual men's HIV related sexual risk behaviour in Scotland. Sex Transm Infect. 75:1999;242-246
72. Dodds JP, Nardone A, Mercey DE, Johnson AM. Increase in high risk sexual behaviour among homosexual men, London 1996-8: cross sectional, questionnaire study. BMJ. 320:2000;1510-1511
73. Elford J, Bolding G, Maguire M, Sherr L. Combination therapies for HIV and sexual risk behavior among gay men. J Acquir Immune Defic Syndr. 23:2000;266-271
74. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS. 15:2001;369-378
75. Dubois-Arber F, Moreau-Gruet F, Jeannin A. Men having sex with men and HIV prevention in Switzerland: 1987-2000. Eurosurveillance. 7:2002;18-18
76. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health. 92:2002;388-394
77. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 75:1999;3-17
78. Grulich A. HIV risk behaviour in gay men: on the rise? BMJ. 320:2000;1487-1488
79. Wolitski RJ, Valdiserri RO, Denning PH, Levine WC. Are we headed for a resurgence of the HIV epidemic among men who have sex with men? Am J Public Health. 91:2001;883-888
80. Royce RA, Sena A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med. 336:1997;1072-1078
81. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: infectiousness and prevention. AIDS. 13:1999;155-166
82. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS. 14:2000;117-121
83. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science. 92:2000;388-394
84. Robert Koch Institut. HIV Infectionen und AIDS-erkrankungen in Deutshchland aktuelle epidemiologische daten (Stand vom 30.6.2003). Epidemiologisches Bulletin 2003; B/2003: 1-16. http://www.rki.de/INFEKT/EPIBULL/ 2003/B_03.PDF (accessed Jan 12, 2004). In German.
85. del Romero J, Castilla J, Garcia S, Clavo P, Ballesteros J, Rodriguez C. Time trend in incidence of HIV seroconversion among homosexual men repeatedly tested in Madrid, 1988-2000. AIDS. 15:2001;1319-1321
86. Janssen RS, Satten AG, Stramer SL, et al. New strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 2080:1998;42-48
87. Dukers NH, Spaargaren J, Geskus RB, Beijnen J, Coutinho RA, Fennema HS. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS. 16:2002;19-24
88. Murphy G, Charlett A, Jordan LF, Osner N, Gill ON, Parry JV. HIV incidence appears constant in men who have sex with men despite widespread use of effective antiretroviral therapy. AIDS. 18:2004;265-272
89. Hamers FF, Batter V, Downs AM, Alix J, Cazein F, Brunet JB. The HIV epidemic associated with injecting drug use in Europe: geographic and time trends. AIDS. 11:1997;1365-1374
90. de la Fuente L, Barrio G, Royuela L, Bravo MJ, The Spanish Group for the Study of the Route of Heroin Administration. The transition from injecting to smoking heroin in three Spanish cities. Addiction 1997; 92: 1749-1763.
91. Strang J, Griffiths P, Powis B, Gossop M. Heroin chasers and heroin injectors: differences observed in a community sample in London, UK. Am J Addict. 8:1999;148-160
92. Smyth BP, O'Brien M, Barry J. Trends in treated opiate misuse in Dublin: the emergence of chasing the dragon. Addiction. 95:2000;1217-1223
93. Welp EA, Lodder AC, Langendam MW, Coutinho RA, van Ameijden EJ. HIV prevalence and risk behaviour in young drug users in Amsterdam. AIDS. 16:2002;1279-1284
94. Haour-Knipe M, Fleury F, Dubois-Arber F. HIV/AIDS prevention for migrants and ethnic minorities: three phases of evaluation. Soc Sci Med. 49:1999;1357-1372
95. Dray-Spira R, Lert F. Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy. AIDS. 17:2003;283-290
96. Sinka K, Mortimer J, Evans B, Morgan D. Impact of the HIV epidemic in sub-Saharan Africa on the pattern of HIV in the UK. AIDS. 17:2003;1683-1690
97. Swedish Institute for Infectious Disease Control. Communicable diseases in Sweden 2001. Stockholm: Karl Ekdahl, 2002. http://www.smittskyddsinstitutet. se/upload/Publikationer/Report2001.pdf (accessed Jan 30, 2004).
98. Institut Scientifique de Santé Publique. Le sida en Belgique. Situation au 30 juin 2003. Rapport semestriel No 57. Brussels: Institut Scientifique de Santé Publique, 2003. http://www.iph.fgov.be/epidemio/ epifr/aidsfr/rap_sem.pdf (accessed Jan 6, 2004). In French.
99. Lot F, Larsen C, Valin N, Gouëzel P, Blanchon T, Laporte A. Parcours sociomédical des personnes originaires d'Afrique subsaharienne atteintes par le VIH, prises en charges dans les hôpitaux d'Ile de France, 2002. Bull Epidemiol Hebdomadaire 2004; 5/2004: 17-20. http://www.invs.sante.fr/beh/ 2004/05/beh_05_2004.pdf (accessed Jan 29, 2004). In French.
100. European Working Group on HIV Infection in Female Prostitutes. HIV infection in European female sex workers: epidemiological link with use of petroleum-based lubricants. AIDS 1993, 7: 401-08.
101. Spina M, Mancuso S, Sinicco A, et al. Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy. Sex Transm Dis. 25:1998;451-454
102. Spizzichino L, Zaccarelli M, Rezza G, Ippolito G, Antinori A, Gattari P. HIV infection among foreign transsexual sex workers in Rome: prevalence, behavior patterns, and seroconversion rates. Sex Transm Dis. 28:2001;405-411
103. D'Antuono A, Andalo F, Carla EM, De Tommaso S. Prevalence of STDs and HIV infection among immigrant sex workers attending an STD centre in Bologna, Italy. Sex Transm Infect. 77:2001;220
104. Belza MJ, Llacer A, Mora R, Morales M, Castilla J, de la Fuente L. Sociodemographic characteristics and HIV risk behaviour patterns of male sex workers in Madrid, Spain. AIDS Care. 13:2001;677-682
105. Verster A, Davoli M, Camposeragna A, Valeri C, Perucci CA. Prevalence of HIV infection and risk behaviour among street prostitutes in Rome, 1997-1998. AIDS Care. 13:2001;367-372
106. Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet. 361:2003;1035-1044
107. Paget WJ, Zwahlen M, Eichmann AR, and the Swiss Network of Dermatovenereology Policlinics. Voluntary confidential HIV testing of STD patients in Switzerland, 1990-1995: HIV test refusers cause different biases on HIV prevalences in heterosexuals and homo/bisexuals. Genitourin Med 1997; 73: 444-447.
108. WHO and UNAIDS. Guidelines for second generation surveillance HIV surveillance. WHO/CDS/CSR/EDC/2000.5, UNAIDS/00.03E. Geneva: WHO/UNAIDS, 2000. http://www.unaids.org/EN/resources/epidemiology/epi_recent_publications/ secondgensurveillance2000.asp (accessed Jun 15, 2004)
109. Rawal BD, Degula A, Lebedeva L, et al. Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr. 33:2003;349-355
110. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and for estimating incidence. AIDS Res Hum Retroviruses. 18:2002;295-307
111. Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr. 32:2002;424-428
112. Girardi E. Epidemiological aspects of transmitted HIV drug resistance. Scand J Infect Dis Suppl. 35:(suppl 106):2003;17-20
113. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA. 284:2000;223-228
114. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 16:2002;1155-1161
115. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 21:2003;3447-3453
116. Marks G, Burris S, Peterman TA. Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility. AIDS. 13:1999;297-306
117. Stephenson JM, Imrie J, Davis MM, et al. Is use of antiretroviral therapy among homosexual men associated with increased risk of transmission of HIV infection? Sex Transm Infect. 79:2003;7-10
118. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS. 16:2002;397-405
119. Levin BR, Bull JJ, Stewart FM. Epidemiology, evolution, and future of the HIV/AIDS pandemic. Emerg Infect Dis. 7:(3 suppl):2001;505-511
120. WHO. Treating 3 million by 2005. Making it happen. The WHO Strategy. Geneva: World Health Organization, 2003. http://www.who.int/entity/3by5/ publications/documents/isbn9241591129/en (accessed Jan 29, 2004)